Patents by Inventor Zhongxing Zhang

Zhongxing Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10998550
    Abstract: According to the present disclosure, a method of fabricating a metal-carbon fibrous structure is provided. The method comprises the steps of: (a) forming a fibrous support structure comprising composite nanocrystals and polymeric fibers, wherein each of the composite nanocrystals comprises metal ions connected by organic ligands; (b) growing the composite nanocrystals on the fibrous support structure; and (c) subjecting the fibrous support structure of step (b) to carbonization to form the metal-carbon fibrous structure, wherein the metal-carbon fibrous structure comprises metal nanoparticles derived from the composite nanocrystals comprising metal organic framework (MOF), particularly zeolitic imidazolate framework (ZIF). A metal-carbon fibrous structure comprising carbon based fibers arranged to form a porous network and the carbon based fibers are doped with metal nanoparticles, wherein the carbon based fibers have surfaces which comprise graphitic carbon, is also disclosed herein.
    Type: Grant
    Filed: January 16, 2017
    Date of Patent: May 4, 2021
    Assignee: Agency for Science, Technology and Research
    Inventors: Suxi Wang, Xu Li, Andy Hor, Zhongxing Zhang, Kia Jia Benny Chew
  • Publication number: 20210023098
    Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, ?2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
    Type: Application
    Filed: October 13, 2020
    Publication date: January 28, 2021
    Inventors: Yasutsugu UEDA, Timothy P. CONNOLLY, John F. KADOW, Nicholas A. MEANWELL, Tao WANG, Chung-Pin H. CHEN, Kap-Sun YEUNG, Zhongxing ZHANG, David Kenneth LEAHY, Shawn K. PACK, Nachimuthu SOUNDARARAJAN, Pierre SIRARD, Kathia LEVESQUE, Dominique THORAVAL
  • Publication number: 20200325127
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: May 9, 2017
    Publication date: October 15, 2020
    Inventors: John F. KADOW, B Narasimhulu NAIDU, Tao WANG, Zhiwei YIN, Zhongxing ZHANG
  • Publication number: 20200255714
    Abstract: A composition includes a hydrofluoroepoxide having Structural Formula (I). Each Rf is, independently, a linear or branched perfluoroalkyl group having 1-6 carbon atoms and optionally comprises a catenated heteroatom.
    Type: Application
    Filed: October 22, 2018
    Publication date: August 13, 2020
    Inventors: Sean Michael Smith, Karl Joseph Warren, Zhongxing Zhang
  • Patent number: 10577353
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: March 3, 2020
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: John F. Kadow, B. Narasimhulu Naidu, Tao Wang, Zhiwei Yin, Zhongxing Zhang
  • Publication number: 20200046743
    Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
    Type: Application
    Filed: October 22, 2019
    Publication date: February 13, 2020
    Inventors: Yasutsugu UEDA, Timothy P. CONNOLLY, John F. KADOW, Nicholas A. MEANWELL, Tao WANG, Chung-Pin H. CHEN, Kap-Sun YEUNG, Zhongxing ZHANG, David Kenneth LEAHY, Shawn K. PACK, Nachimuthu SOUNDARARAJAN, Pierre SIRARD, Kathia LEVESQUE, Dominique THORAVAL
  • Publication number: 20190359750
    Abstract: Described herein is a partially fluorinated copolymer of the formula: (I); wherein R1 is selected from F or a fluorinated methyl; R2 is selected from H, F, a methyl, or a (per)fluorinated methyl; R3? is a linear or branched fluorinated alkyl group comprising 1 to 12 carbon atoms, optionally with at least one catenated oxygen atom; p is 0, 1, or 2; r is 0 or 1; and Q comprises at least one of an hydroxide, a nitrile, an ester, a silane, a siloxane, a phosphoric acid or salt thereof, a sulphuric acid or salt thereof, an alkyl, an aryl, and combinations thereof; n is an integer of at least 2; and m is an integer of at least 2.
    Type: Application
    Filed: December 12, 2017
    Publication date: November 28, 2019
    Inventors: Yu Yang, Klaus Hintzer, Zhipeng Song, Zhongxing Zhang, Dong-Wei Zhu
  • Patent number: 10465147
    Abstract: Described herein are copolymers comprising at least one first water-soluble monomeric unit, at least one second water-soluble monomeric unit, and at least one monomeric unit containing a basic residue.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: November 5, 2019
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Jun Li, Zhongxing Zhang, Xian Jun Loh, Xiping Ni
  • Patent number: 10407410
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: September 10, 2019
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: John F. Kadow, B. Narasimhulu Naidu, Manoj Patel, Michael A. Walker, Tao Wang, Zhiwei Yin, Zhongxing Zhang, Zhizhen Barbara Zheng
  • Publication number: 20190152957
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: May 9, 2017
    Publication date: May 23, 2019
    Inventors: John F. KADOW, B. Narasimhulu NAIDU, Tao WANG, Zhongxing ZHANG
  • Publication number: 20190127351
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: May 9, 2017
    Publication date: May 2, 2019
    Inventors: John F. KADOW, B. Narasimhulu NAIDU, Manoj PATEL, Michael A. WALKER, Tao WANG, Zhiwei YIN, Zhongxing ZHANG, Zhizhen Barbara ZHENG
  • Publication number: 20190111066
    Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
    Type: Application
    Filed: November 14, 2018
    Publication date: April 18, 2019
    Inventors: Yasutsugu UEDA, Timothy P. CONNOLLY, John F. KADOW, Nicholas A. MEANWELL, Tao WANG, Chung-Pin H. CHEN, Kap-Sun YEUNG, Zhongxing ZHANG, David Kenneth LEAHY, Shawn K. PACK, Nachimuthu SOUNDARARAJAN, Pierre SIRARD, Kathia LEVESQUE, Dominique THORAVAL
  • Publication number: 20190092754
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: November 28, 2018
    Publication date: March 28, 2019
    Inventors: Kyle J. EASTMAN, John F. Kadow, Kyle E. Parcella, B. Narasimhulu Naidu, Tao Wang, Zhiwei Yin, Zhongxing Zhang
  • Patent number: 10214516
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: February 26, 2019
    Assignee: VIIV HEALTHCARE UK (NO.5) LIMITED
    Inventors: John F. Kadow, B. Narasimhulu Naidu, Tao Wang, Zhiwei Yin, Zhongxing Zhang
  • Patent number: 10214534
    Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: February 26, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhongxing Zhang, Kyle E. Parcella, Kyle J. Eastman, John F. Kadow
  • Patent number: 10202403
    Abstract: Compounds of formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: February 12, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhongxing Zhang, John F. Kadow
  • Patent number: 10189816
    Abstract: Disclosed are compounds of Formula (I), including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: January 29, 2019
    Assignee: ViiV HEALTHCARE UK (NO. 5) LIMITED
    Inventors: Kyle J. Eastman, John F. Kadow, Kyle E. Parcella, B. Narasimhulu Naidu, Tao Wang, Zhiwei Yin, Zhongxing Zhang
  • Publication number: 20190020028
    Abstract: According to the present disclosure, a method of fabricating a metal-carbon fibrous structure is provided. The method comprises the steps of: (a) forming a fibrous support structure comprising composite nanocrystals and polymeric fibers, wherein each of the composite nanocrystals comprises metal ions connected by organic ligands; (b) growing the composite nanocrystals on the fibrous support structure; and (c) subjecting the fibrous support structure of step (b) to carbonization to form the metal-carbon fibrous structure, wherein the metal-carbon fibrous structure comprises metal nanoparticles derived from the composite nanocrystals comprising metal organic framework (MOF), particularly zeolitic imidazolate framework (ZIF). A metal-carbon fibrous structure comprising carbon based fibers arranged to form a porous network and the carbon based fibers are doped with metal nanoparticles, wherein the carbon based fibers have surfaces which comprise graphitic carbon, is also disclosed herein.
    Type: Application
    Filed: January 16, 2017
    Publication date: January 17, 2019
    Inventors: Suxi Wang, Xu Li, Andy Hor, Zhongxing Zhang, Kia Jia Benny Chew
  • Patent number: 10144706
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: December 4, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Katharine A. Grant-Young, Juliang Zhu, Mark G. Saulnier, David B. Frennesson, David R. Langley, Piyasena Hewawasam, Tao Wang, Zhongxing Zhang, Zhaoxing Meng, Li-Qiang Sun, Eric Mull, Paul Michael Scola
  • Patent number: 10125111
    Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus, (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: November 13, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhiwei Yin, Zhongxing Zhang, John F. Kadow